TGME49_240640

Toxoplasma gondii encodes two enzymatically active casein kinase I isoforms, TgCK1alpha (38 kDa) and TgCK1beta (49 kDa), both confirmed to have kinase activity when immunoprecipitated from transfected parasites and when produced recombinantly in E. coli (PMID:15811523). The two isoforms differ in localization: TgCK1alpha is cytosolic while TgCK1beta associates predominantly with the plasma membrane, an association conferred by its C-terminal extension domain (PMID:15811523). TgCK1alpha appears to be the predominant native tachyzoite enzyme, as a native 38 kDa CK1 activity purified from tachyzoite lysates matches recombinant TgCK1alpha biochemically and serologically, with no corresponding native TgCK1beta activity detected (PMID:15811523). TgCK1alpha activity is selectively inhibited by the purvalanol compounds purvalanol B and aminopurvalanol A, and cell-permeable aminopurvalanol A also blocks parasite growth, indicating structural differences from host CK1 that can be pharmacologically exploited (PMID:15811523). Beyond this biochemical and pharmacological characterization, the physiological substrates and downstream pathways of the T. gondii CK1 isoforms have not been characterized in the available corpus.

1. 2005 High

   Establishing whether T. gondii encodes functional CK1 enzymes was the first step; cloning and biochemical characterization confirmed two active isoforms, defining CK1 as a genuine parasite kinase family.

   Evidence PCR cloning, FLAG-tagged transient transfection with immunoprecipitation kinase assay, and recombinant E. coli expression in T. gondii

   PMID:15811523

   Open questions at the time

   • Physiological substrates of neither isoform identified
   • No genetic knockout to establish in vivo requirement
2. 2005 High

   To distinguish the two isoforms functionally, localization and domain mapping showed TgCK1alpha is cytosolic and TgCK1beta is plasma-membrane targeted via its C-terminal extension, indicating spatially segregated roles.

   Evidence Subcellular localization of FLAG-tagged constructs and C-terminal deletion mapping in transiently transfected T. gondii

   PMID:15811523

   Open questions at the time

   • Mechanism of C-terminal membrane targeting (lipidation vs. protein interaction) unknown
   • Localization shown in transient transfection, not for endogenous protein
3. 2005 Medium

   Whether the recombinant isoforms reflect native parasite enzymes was addressed by purifying endogenous CK1 activity, revealing TgCK1alpha as the predominant native tachyzoite kinase with no detectable native TgCK1beta activity.

   Evidence Partial purification from tachyzoite lysates by ion-exchange and hydrophobic interaction chromatography with kinase and serological characterization

   PMID:15811523

   Open questions at the time

   • Negative result for native TgCK1beta may reflect low abundance rather than absence
   • Stage-specific expression of TgCK1beta not tested
4. 2005 Medium

   To test therapeutic exploitability, selective inhibition of TgCK1alpha by purvalanol compounds and growth inhibition by cell-permeable aminopurvalanol A established parasite CK1 as a druggable target distinct from host CK1.

   Evidence In vitro kinase inhibition assays with recombinant TgCK1alpha and parasite growth inhibition assays

   PMID:15811523

   Open questions at the time

   • Growth inhibition not formally shown to act through CK1 in vivo
   • Selectivity over host CK1 inferred, not directly compared
   • Which isoform mediates the growth phenotype unresolved

• The physiological substrates, downstream signaling pathways, and genetic requirement of each T. gondii CK1 isoform remain unknown.
• No substrates identified for either isoform
• No knockout/conditional depletion to establish essentiality
• No structural model explaining host-parasite CK1 inhibitor selectivity